Management of adverse effects of new monoclonal antibody treatments in acute lymphoblastic leukemia
Therapeutic options for relapsed/refractory B-cell acute lymphoblastic leukemia have evolved in the past few years. The FDA has approved three novel therapies for this disease: inotuzumab ozogamicin (an anti-CD22 antibody–drug conjugate), blinatumomab (a bispecific T-cell engager), and chimeric anti...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioExcel Publishing Ltd
2020-10-01
|
| Series: | Drugs in Context |
| Subjects: | |
| Online Access: | https://www.drugsincontext.com/management-of-adverse-effects-of-new-monoclonal-antibody-treatments-in-acute-lymphoblastic-leukemia |